VP, DMD Commercial Asset Lead

Dyne Therapeutics•Waltham, MA

28d•$272,000 - $340,000•Onsite

About The Position

The VP, DMD Commercial Asset Lead (CAL) is a passionate driver for maximizing the value of Dyne’s DMD commercial assets with a global perspective, who brings adaptable leadership to develop and implement commercialization strategies to maximize the reach and value creation of Dyne’s DMD commercial assets in the neuro muscular portfolio. This mandate includes market analysis, competitive positioning, launch readiness and execution and input into lifecycle management in the relentless pursuit of long-term success in bringing the asset to patients globally. The CAL is a highly visible leadership role. As a key member of an experienced Program Team, the CAL will work with the cross-functional team to influence and shape the Program strategy. The CAL leads all efforts in defining the commercialization strategy, strategic imperatives, critical success factors, executional priorities, and launch efforts together with the launch teams of the affiliates, bringing both a 'future-orientation' toward the goal of broad, global access for patients in need, and a "pragmatic-orientation" to chart the path, mitigate risks, cultivate options. The CAL collaborates with program team, functional leads and affiliate teams to achieve a differentiated product profile, competitive label, broad reimbursement and highly successful launches globally starting with the US launch. The CAL, as a member of the program team, is responsible for securing commercialization and works hand in hand in strong partnership with the Program Lead, the Head of Commercialization, all functional leaders and the affiliate launch teams. This role is based onsite in Waltham, MA.

Requirements

Bachelor’s degree in a relevant scientific, medical, or business discipline required; advanced degree (MD, PhD, PharmD, MBA, or Master’s in Life Sciences) strongly preferred.
Minimum of 20 years of experience in the biopharmaceutical industry.
15+ years of commercialization and cross-functional leadership experience within the biopharmaceutical industry, including substantial involvement in clinical development strategy, regulatory interactions, filing preparation, and lifecycle planning.
Extensive experience leading global product launches, including development of launch strategy, execution, and cross-functional commercialization planning.
Rare disease launch experience strongly preferred; neuromuscular disease experience highly advantageous.
Proven track record of:
Delivering on business objectives in fast--paced, highstakes environments.
Steering assets from late stage development through approval and launch.
Influencing global and U.S. market access, value evidence generation, and reimbursement readiness.
Experience collaborating closely with clinical development, medical affairs, supply chain, marketing, digital/data teams, and affiliate launch organizations.
Expertise in global asset commercialization, including competitive positioning, launch sequencing, market shaping, and lifecycle strategy.
Ability to synthesize scientific, clinical, regulatory, and market data to guide asset and commercialization strategy.
Fluency with digital launch tools, analytics platforms, and data driven decision-making.
Entrepreneurial, self-driven leader capable of articulating a compelling vision and mobilizing high performing cross functional teams.
Strong people leadership skills with the ability to coach, influence, and inspire diverse functional experts.
Exceptional communication skills, including clear and effective engagement with executive leadership, affiliates, external partners, Boards of Directors, and patient communities.
Proven ability to build strong, credible relationships with KOLs, advocacy groups, payers, regulators, and other key stakeholders.
Comfortable leading through ambiguity, adapting to evolving priorities, and driving alignment in a dynamic environment.
High integrity, strong patient centric mindset, and alignment with Dyne’s core values.
Strong sense of urgency with the ability to pace and prioritize workstreams in competitive and fast-moving environments.
Transparent, inclusive communicator with a collaborative leadership style.

Responsibilities

Define global asset commercialization strategy and plan to achieve milestones and timelines for successful launches
As a key member of the Program Team and Head of DMD Commercial Sub Team, they ensure that all key pillars for successful commercialization for the assets are secured – starting with differentiation in endpoints to achieve a competitive product profile/label, regulatory strategy, filing strategy, with value & access to secure the value proposition for the assets and achieve reimbursement in US and at the right time globally, partner with supply, medical, marketing, digital and the data team to prepare successful launch strategy and execution for all key markets starting with US.
Provide input and expertise to a robust and well-understood program strategy with the key objective of gaining the approvals of potentially life-changing medicines for patients around the world to generate value for patients and shareholders and maximize topline growth.
Structure and facilitate critical cross-functional decisions on commercialization aspects of the asset within Program Teams and senior leadership teams, bringing all relevant perspectives to bear while driving to efficient decisions in a fast-paced environment.
Working with cross-functional launch team in key markets, starting with the US team, and Strategic Commercialization Partners to secure reimbursement and successful launches, by propelling successful launch execution from one country to the other.
In close collaboration with the Program Lead and Head of Commercialization, consider and advocate for the needs of the commercial asset in the context of Dyne’s corporate strategy and priorities.
Drive preparation and presentation of materials for Board of Directors on asset commercialization topics
Maintain clear, open, and proactive communication with the senior leadership team and other stakeholders regarding commercialization strategy, status, priorities, risks and needs, and facilitate appropriate decision-making.
Keep abreast of competitor landscape and development in the fields of muscle diseases and oligonucleotide drug discovery and development.
Build visible, constructive, and credible presence within the DMD community including with KOLs, the holistic teams engaged in patient care and patient community.
Participate in business development activities, as needed, including opportunity evaluations and due diligence.
Provide a motivating leadership example within Dyne more broadly during periods of rapid growth.
Foster a culture of collaboration, innovation, discovery, and cutting-edge research.
Focused on scientific excellence, open communication, and continuous improvement.
Role model Dyne’s core values.